Watch LAB. Know when insiders buy.
One email the day a filing lands. Free.
LAB
STANDARD BIOTOOLS INC.
0.77
+0.04 +5.48%
USD · close Sep 18
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
2
FLAG · shorts 2
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $302.3MP/E 3.5DIV YIELD —FCF YIELD -27.32%REV TTM $84.6M −4.8%NET INCOME $84.9MNET CASH $269.7M52W 0.64 – 1.68SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $20.1M | −7.6% | 52.4% | −$25.4M | −$26.8M | — | -0.07 | −$10.3M | $344K | −$10.7M | Aug 5 |
| Q1 2026 · Mar 31 | $21.1M | +4.6% | 53.5% | −$12.5M | $127.1M | — | 0.33 | −$46.6M | $570K | −$47.2M | Aug 5 |
| Q4 2025 · Dec 31derived | $23.8M | −4.0% | 47.8% | −$24.6M | $19.3M | — | 0.05 | −$1.2M | $476K | −$1.7M | Mar 16 |
| Q3 2025 · Sep 30 | $19.6M | −11.5% | 48.5% | −$32.9M | −$34.7M | — | -0.09 | −$22.2M | $886K | −$23.1M | Nov 4 |
| Q2 2025 · Jun 30 | $21.8M | −3.2% | 48.8% | −$25.7M | −$33.5M | — | -0.09 | −$20.7M | $1.9M | −$22.6M | Aug 5 |
| Q1 2025 · Mar 31 | $20.2M | −55.6% | 54.6% | −$27M | −$26M | — | -0.07 | −$30.3M | $5.1M | −$35.3M | Aug 5 |
| Q4 2024 · Dec 31derived | $24.8M | −12.1% | 45.8% | −$26.1M | −$34.1M | — | -0.08 | −$14.1M | $3.4M | −$17.4M | Mar 16 |
| Q3 2024 · Sep 30 | $22.1M | −12.9% | 54.9% | −$26.7M | −$26.9M | — | -0.07 | −$27.9M | $2.3M | −$30.1M | Nov 4 |
| Q2 2024 · Jun 30 | $22.5M | — | 46.1% | −$30.3M | −$45.7M | — | -0.12 | −$39M | $1.9M | −$41M | Nov 4 |
| Q1 2024 · Mar 31 | $45.5M | — | 53.1% | −$60.2M | −$32.2M | — | -0.27 | −$62.5M | $781K | −$63.3M | Nov 4 |
| Q4 2023 · Dec 31derived | $28.2M | — | 47.4% | −$21.4M | −$19.8M | — | -0.25 | −$14.1M | $78K | −$14.1M | Mar 16 |
| Q3 2023 · Sep 30 | $25.4M | — | 44.0% | −$21.2M | −$21M | — | -0.27 | −$11.4M | $905K | −$12.3M | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $85.3M | 49.9% | −$110.2M | −$74.9M | -87.8% | -0.20 | −$74.3M | $8.3M | −$82.6M | $0 | — |
| FY2024 · to Dec 31 | $91M | 49.3% | −$127.5M | −$138.9M | -152.6% | -0.52 | −$143.5M | $8.4M | −$151.8M | $40.5M | — |
| FY2023 · to Dec 31 | $106.3M | 47.4% | −$76.6M | −$74.7M | -70.2% | -0.94 | −$43.3M | $2.8M | −$46.1M | $5.4M | — |
| FY2022 · to Dec 31 | $97.9M | 37.8% | −$116.2M | −$190.1M | -194.1% | -2.43 | −$89.4M | $3.8M | −$93.2M | $563K | — |
| FY2021 · to Dec 31 | $130.6M | — | −$67.5M | −$59.2M | -45.4% | -0.78 | −$44.1M | $13.3M | −$57.3M | $0 | — |
| FY2020 · to Dec 31 | $138.1M | — | −$51M | −$53M | -38.4% | -0.74 | −$15.4M | $12.7M | −$28.1M | — | — |
Every number comes from STANDARD BIOTOOLS INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.